Why Drying Cannabis is Making Investors Money-THC Therapeutics, Inc. (USOTC: THCT)
May 7, 2019 -- InvestorsHub NewsWire -- Microcap Speculators -- One way in which cannabis producers can differentiate and strengthen their product is through drying their crops properly. That’s why there is a cottage industry of cannabis-specific drying tech that is starting to form. One company with a vacuum tech, EnWave, just signed a $10m deal with cannabis giant Aurora Cannabis.
Looking for the next EnWave that big cannabis companies may come calling for, we’ve come across is THC Therapeutics, Inc. (USOTC: THCT). They very recently, announced that they have received full patent protection for The dHydronator®, which can reduce moisture content of cannabis to 10% in only 10-14 hours (normally it takes up to 14 days). The US patent office accepted ALL 20 claims for The dHydronator®. The dHydronator® also destroys harmful surface contaminants & pathogens. The term of the patent provides 20 years of protection on the scalable intellectual property for The dHydronator®. This is big news from THCT.
Today we are highlighting: THC Therapeutics, Inc. (USOTC: THCT), EnWave (NWVCF), Valens GrowWorks Corp. (USOTC: VGWCF), The Brink’s Company (NYSE: BCO), and Aleafia Health, Inc. (USOTC: ALEAF).
THC Therapeutics, Inc. (USOTC: THCT) (Market Cap: $124.887M; Share Price: $9.61) has developed a sanitizing herb dryer, The dHydronator®. Their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis and herbs. THCT’s product has been tested by two independent laboratories. The testing covered over 6 strains and 9 independent tests to confirm the findings. Over the 9 tests and 6 strains, there was a 4% average increase of THC-A*.
The US patent office has accepted ALL 20 claims for The dHydronator®. The company has received full patent protection for the dHydronator®. Start your research today on THCT.
EnWave Corporation (NWVCF) (Market Cap: $162.757M; Share Price: $1.8583) mentioned earlier in the article, is the vacuum company Aurora just signed a deal with.
Valens GrowWorks Corp. (USOTC: VGWCF) (Market Cap: $339.176M; Share Price: $3.21) has rallied after GMP Securities raised its stock price target after the company’s latest quarterly earnings. GMP analyst, Martin Landry, boosted his price target to $10 from $8 and reiterated his buy rating. Valens’ first-quarter earnings were in line and are mostly immaterial to its earnings power as it remains in the early stages of its growth cycle, he wrote.
But the company’s comments on demand for its extraction services support Landry’s fiscal 2020 forecasts, he wrote in a note to clients, and the company is an ideal partner for potential international consumer packaging companies seeking to source a cannabis-derived product in Canada. Valens is aiming to be the biggest third-party vape pen manufacturer and distributor in Canada, and is developing formulations for drinks and edibles, which will become fully legal in Canada in October.
The experience that security company, The Brink’s Company (NYSE: BCO) (Market Cap: $3.993B; Share Price: $80.06), is building in Canada could be a boon if the U.S. fully legalizes cannabis at the federal level. Brink’s is currently offering cash and logistics service to Canopy Growth.
BCO is not currently serving the U.S. sector, but Chief Executive, Doug Pertz, told analysts on the company’s earnings call that the company supports legislation that would allow banks to work with companies in states that have legalized, as a matter of public safety and policy.
Aleafia Health, Inc. (USOTC: ALEAF) (Market Cap: $278.425M; Share Price: $1.218) provided a corporate update and report on its financial results for the year-ended December 31, 2018.
“2018 saw Aleafia Health build the foundation for a breakthrough 2019 and beyond. We believe that our strategically placed assets, strong management team and distribution channels will allow us to scale our global mission of growing, processing and selling high-margin, value-added cannabis health and wellness products,” said Aleafia Health CEO Geoffrey Benic. “It is a testament to the executional capabilities and commitment of our team that Aleafia Health has grown from a pre-revenue business to one of the largest licensed producers in under one year.”
Priyanka Goel, CFA
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a three-month term consulting agreement with THCT dated 2/14/18. The agreement calls for 50,000 restricted shares of THCT per month. This agreement has been amended to $20,000 per month, and 55,000 shares per month and extended for twelve months ending 3/18/2020. All payments were made directly by THC Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. THCT was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Full Legal Disclaimer Click Here.
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Country: United States
SOURCE: Microcap Speculators